Marfan syndrome is a genetic disorder affecting connective tissue. Angiotensin receptor blockers (ARBs) have shown promise in slowing the rate of aortic root dilation in Marfan patients compared to traditional treatments like beta blockers. This is believed to be due to ARBs' ability to inhibit transforming growth factor beta (TGF-β) signaling, which regulates extracellular matrix degradation. A clinical trial found that children treated with losartan saw their aortic root growth rate reduced nearly eight-fold compared to an untreated control group. More research is still needed to determine how different Marfan mutations may respond differently to ARB treatment.